RxDoctor Payments Data

Pierre Atallah, MD

Cardiovascular Disease · Rochester, MINPI 1306158993

Payments from drug & device makers

$1,447in general payments, 2019–2025

Across 52 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$397
  • Pfizer$181
  • Amarin Pharma, Inc.$167
  • Heartflow, Inc.$163
  • Esperion Therapeutics, Inc.$150
  • Cleerly, Inc.$68
  • plus $322 from 10 others

What the payments were for

  • Food & beverage$1,42799%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,447 in reported general payments places this provider in the 35th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$371,889
Medicare patients
198
Services billed
2,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$82,931
EliquisApixaban58$69,462
TrulicityDulaglutide32$60,384
FarxigaDapagliflozin Propanediol12$19,401
Repatha SureclickEvolocumab18$15,987
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,765
Rosuvastatin Calcium410$10,455
VascepaIcosapent Ethyl19$10,377
Metoprolol Succinate407$8,333
Icosapent Ethyl11$5,333
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,594
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide136$2,934
Losartan Potassium194$2,606
Ranolazine ErRanolazine11$2,182
Atorvastatin Calcium114$1,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$20$82,93156 claims
PfizerEliquis$181$69,46258 claims
Lilly USA, LLCTrulicity$15$60,38432 claims
AstraZenecaFarxiga$61$19,40112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Rochester

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →